Class III beta-tubulin overexpression within the tumor microenvironment is a prognostic biomarker for poor overall survival in ovarian cancer patients treated with neoadjuvant carboplatin/paclitaxel

✍ Scribed by Roque, D.; Buza, N.; Glasgow, M.; Ratner, E.; Silasi, D.; Azodi, M.; Rutherford, T.; Schwartz, P.; Santin, A.

• Book ID: 121978244
• Publisher: Elsevier Science
• Year: 2013
• Tongue: English
• Weight: 334 KB
• Volume: 130
• Category: Article
• ISSN: 0090-8258
• DOI: 10.1016/j.ygyno.2013.04.358